AU Patent

AU2016208417B2 — Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate

Assigned to Janssen Sciences Ireland ULC · Expires 2018-04-05 · 8y expired

What this patent protects

H:Vec\Interwoven\NRPortbl\DCC\REC\I0602794_I.docx-28/07/2016 Abstract The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of

USPTO Abstract

H:Vec\Interwoven\NRPortbl\DCC\REC\I0602794_I.docx-28/07/2016 Abstract The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of

Drugs covered by this patent

Patent Metadata

Patent number
AU2016208417B2
Jurisdiction
AU
Classification
—
Expires
2018-04-05
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.